Zoomed Image
  • Empiget 10mg Tablets 14's

Empiget 10mg Tablets 14's

Empiget (Empagliflozin) tablets contain empagliflozin, an orally-active inhibitor of the sodium-glucose co-transporter 2 (SGLT2). Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose and thereby increases urinary glucose excretion. Empiget (Empagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus as:
Monotherapy: When diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
Add-on combination therapy: In combination with other glucose–lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycemic control.
How to use
Monotherapy and add-on combination therapy: The recommended starting dose is 10mg empagliflozin once daily with or without food for monotherapy and add-on combination therapy with other glucose-lowering medicinal products including insulin. In patients tolerating empagliflozin 10mg once daily who have an eGFR ≥60 ml/min/1.73 m2 and need tighter glycemic control, the dose can be increased to 25mg once daily. The maximum daily dose is 25mg. When empagliflozin is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycemia .
Empagliflozin is contraindicated in:
• Patients with known hypersensitivity to empagliflozin or to any excipient of the product.
• Severe renal impairment, end-stage renal disease, or dialysis.